To determine whether BCRP mediates resistance to TAK-243 in other cell lines, we treated A549 lung cancer cells, MCF7 breast cancer cells, MDAY-D2 lymphosarcoma cells (27), and RPMI 8226 myeloma cells with TAK-243 alone and in combination with Ko143 or zosuquidar. This evidence concerns the gene ABCG2 and breast carcinoma.